We found that the pre-treatment absolute numbers of circulating monocytes, and of CD14+highCD16−, CD14+highCD16+ and CD14+lowCD16+ subset cells, predict the clinical response to MTX in untreated patients with RA. Here, CD14 is linked to rheumatoid arthritis.